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Acute decompensated heart failure (ADHF) is a difficult clin-
ical problem with poor outcomes. High in-hospital mortality
and readmissions remain a concern despite advancement of
treatment options for heart failure [1, 2]. The presence of com-
plicating factors such as ventricular arrhythmias, renal dys-
function, or ischaemic heart disease (with or without hibernat-
ing myocardium) makes the management more complex and
the outcomes bleaker [3–5]. However, newer treatment op-
tions continue to appear and further research continues. A
focused look at these complicated ADHF scenarios is there-
fore helpful in assessing where we currently are in tackling
these syndromes and what is just around the corner. Such
focus is also likely to lead to new targeted thinking towards
better avenues of management.
The previously dreaded ventricular arrhythmias in chronic
heart failure have been managed much more effectively since
the introduction of the implantable cardioverter–defibrillators
(ICDs) [6]. However, recurrent VT despite optimal medical
and cardiac resynchronisation therapy remains a problemwith
the affected patients occasionally experiencing recurrent
shocks amounting to an electrical storm that can be very
distressing to the patients [7]. Catheter ablation for ventricular
tachycardia has come a long way but can it be used safely and
effectively in such patients, especially those with refractory
VT in ADHF? Dimitropoulos G and coauthors have, in their
review, provided all the evidence available on VT ablation in
both chronic and acute heart failure settings which clearly
shows VT ablation to be an effective tool in ADHF but it
needs to be tested further in larger trial settings.
Renal dysfunction in a heart failure patient is common
and cardiorenal syndrome is now an established term.
ADHF often brings with it worsening renal function and
acute kidney injury that can raise concerns about the use
of the much needed intravenous diuretic therapy as well
as demand adjustment in ACE inhibitors, angiotensin re-
ceptor antagonists, or sacubutril valsartan [5]. Progressive
renal dysfunction during a hospital admission with
ADHF invariably prompts a referral to the renal physi-
cians for renal support including dialysis. The review by
Bielecka-Dabrowa A and coauthors highlights important
new treatment options for future consideration using ad-
ditional hypertonic saline with intravenous diuretics and
tolvaptan which conserve renal function while still
effecting adequate diuresis. Emerging markers for assess-
ment of prognosis and the role of dialysis in this setting
are discussed.
Although research involving hibernating myocardium
is almost exclusively confined to the stable chronic heart
failure population, the heart failure clinician frequently
encounters it in ischaemic acute heart failures with a tro-
ponin rise. Ryan and Perera highlight the importance of
considering coronary angiography if appropriate and
where possible in ADHF for better management planning.
We are also informed of the important REVIVED-BCIS2
trial, a UK multicentre study that randomises ischaemic
heart failure into revascularisation by percutaneous inter-
vention or optimal medical treatment and incorporates hi-
bernating myocardium.
The reviews in this series on complicated acute heart failure
syndromes bring up exciting future directions in managing
these difficult subsets which often overlap. Tackling these
subsets effectively is likely to go a long way in reducing mor-
tality and hospitalisation rates.
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